HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Advanced Triple Negative Breast Cancer

Interventions

DRUG

Camrelizumab

PD-1 inhibitor

DRUG

Nab-paclitaxel

chemotherapy

DRUG

SKB264

Trop2-ADC

DRUG

Lenvatinib

Anti-angiogenic TKI

Trial Locations (1)

Fudan Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER